The MICHELLE trial found rivaroxaban thrombo-prophylaxis beneficial for COVID-19 patients. Some individuals had a 67% risk reduction in clinical outcome composites.
Amidst anti-vaccine passport demonstrators, a masked Dr. Haegy stands alone, with a handmade sign reminding us of some figures: 2,000 intensive care patients, of which 85% were not vaccinated.
A meta-analysis of three large primary prevention trials showed fixed-dose combination treatments help prevent CV death, MI, stroke, or revascularisation.
The FIGARO-DKD trial investigated mineralocorticoid receptor antagonist treatment effects on cardiovascular outcomes in patients with mild-to-moderate kidney disease and T2D.
The DECIDE-Salt trial assessed dietary sodium-reduction strategies over 2 years in residential care patients, targeting significant reductions in systolic blood pressure.
The study showed that diabetic patients with symptomatic PAD and recent peripheral artery revascularisation share benefits from low-dose rivaroxaban with non-diabetics.
Starting with a quadruple combination of hypertensive agents in tiny doses showed to be more effective than standard monotherapy in blood pressure (BP) control.
A novel analysis of DAPA-HF investigated the efficacy of dapagliflozin on ventricular arrhythmia, resuscitated cardiac arrest, and sudden death showing a very reduced likelihood for composite outcome by 21%.
Breathing problems may more frequently precede cardiac arrest than chest pain. Further research can help emergency dispatchers distinguish between symptoms.
The NATURE-PCSK9 study revealed that a yearly vaccine-like approach with PCSK9 small-interfering RNA can reduce cardiovascular events up to two thirds. ‘The earlier the better’ applies in LDL reduction.
The GUIDE-HF trial showed benefits of haemodynamic-guided HF management with an implantable device in reducing HF hospitalisations.
Certain immune cells that people have produced in the past against cold coronaviruses boost the immune response against SARS-CoV-2 - both during natural infection and after vaccination.
Anticoagulation strategies for atrial fibrillation (AF) with edoxaban or vitamin K antagonists (VKA) were evaluated in patients post transcatheter aortic valve implantation (TAVI) in the ENVISAGE-TAVI AF trial.
A trial investigated valsartan's potential in slowing HCM disease course , with a significantly positive influence on relative cardiac remodelling in the valsartan group.
The landmark trial shwowed a clinically meaningful 21% reduction in primary composite outcomes and positive results in secondary outcomes with empagliflozin therapy for HFpEF patients.
An implanted heart monitor detects more signs of dangerous complications in patients who have survived a heart attack than conventional follow-up care.
Prof. Peschanski shares the tragic story of how, in 1998, he first encountered the anti-vaxxer world. A painful story that he never shared until today, encouraged by the controversies over COVID vaccines.
Dr. Joris Galland explores ways in which physicians and AI can work together and compliment each other in the future of healthcare.
TU Dresden researchers developed a bio-compatible implantable AI platform that classifies healthy and pathological patterns in biological signals and detects pathological changes without medical supervision.
Marie Curie is associated with many subjects, and rightly so: With two Nobel prizes won within eight years of each other, she remains one of the most famous scientists of the 20th century.